Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Group 1 - Rigel Pharmaceuticals announced upcoming presentations at the 2024 ASCO Annual Meeting and EHA 2024 Congress, showcasing their hematology and oncology portfolio [1][2] - Presentations will include data on REZLIDHIA® (olutasidenib) for mutated IDH1 acute myeloid leukemia (AML) and TAVALISSE® (fostamatinib) for chronic immune thrombocytopenia (ITP), along with a Phase 1b trial of R2891 [2][3] - The five-year data from the Phase 2 trial of REZLIDHIA indicates rapid and durable responses, particularly in difficult-to-treat populations, including elderly patients [3][6][7] Group 2 - TAVALISSE demonstrated efficacy as a second-line therapy for ITP, allowing successful tapering of corticosteroids while maintaining platelet counts above 50,000/μL [4][10] - The ASCO and EHA presentations will include various abstracts highlighting the efficacy and safety of olutasidenib in different patient populations, including those with relapsed or refractory AML [5][8][11] - Observational studies provide real-world insights into the use of fostamatinib in ITP patients, emphasizing the need for additional treatment options [10][15] Group 3 - Rigel Pharmaceuticals focuses on developing therapies for hematologic disorders and cancer, with a commitment to improving patient outcomes [36] - The company has a robust pipeline, including investigational compounds like R289, which targets IRAK1 and IRAK4 for lower-risk myelodysplastic syndrome [16][36] - Rigel's marketed products and ongoing clinical trials reflect its dedication to addressing unmet medical needs in hematology and oncology [36][37]